Atebimetinib is an investigational new drug that is being developed by Immuneering Corporation for the treatment of pancreatic cancer. It is a dual MEK1/MEK2 inhibitor of mitogen-activated protein kinase kinase.
The compounds of every Wikipedia article carrying a Chembox or a Drugbox, refreshed daily, with the values their infoboxes give. The pages need JavaScript; the API does not.